: ,

Investors

POZEN News Archive

Date Title and Summary
Toggle Summary POZEN Announces Effectiveness Of Aralez Registration Statement On Form S-4 And Provides Update On Key Milestones For 2016
- POZEN schedules stockholder meeting for February 2 , 2016-  -Plan to re-file YOSPRALA™ New Drug Application early in the second quarter; Approval and launch targeted in fourth quarter-  CHAPEL HILL, N.C. , Dec. 28, 2015 /PRNewswire/ --   POZEN Inc.
Toggle Summary POZEN And Tribute Announce Plan To Proceed With Merger To Form Aralez Pharmaceuticals
- US$350 Million Capital Commitment from Deerfield-Led Syndicate- -Canada Domicile Provides Similar Competitive Structure and Benefits to Ireland - -Previously Scheduled Shareholder Meetings of POZEN and Tribute to be Rescheduled- CHAPEL HILL, N.C. and MILTON, Ontario , Dec.
Toggle Summary POZEN And Tribute Provide Update On Pending Combination Transactions
-POZEN and Tribute Evaluating Canadian Domicile for Aralez Pharmaceuticals- CHAPEL HILL, NORTH CAROLINA and MILTON, ONTARIO -- ( Marketwired ) -- 11/23/15 -- POZEN Inc. ("POZEN") (NASDAQ:POZN) and Tribute Pharmaceuticals Canada Inc. ("Tribute") (TSX VENTURE:TRX) (OTCQX:TBUFF) today provided an
Toggle Summary POZEN Reports Third Quarter 2015 Results
Strategic Merger with Tribute Pharmaceuticals Still on Track to Close in December 2015 Commercial Launch Preparation Efforts for YOSPRALA TM Well Underway CHAPEL HILL, N.C. --(BUSINESS WIRE)--Nov. 9, 2015-- POZEN Inc. (NASDAQ: POZN) , today announced results for the third quarter ended September
Toggle Summary POZEN Inc. to Announce Third Quarter 2015 Results on November 9, 2015
Company to host call at 11:00 a.m. ET CHAPEL HILL, N.C. --(BUSINESS WIRE)--Oct. 26, 2015-- POZEN Inc. (NASDAQ: POZN) today announced that the Company plans to release results for the third quarter 2015 on Monday, November 9, 2015 , before the opening of the U.S. markets.
Toggle Summary POZEN to Present at the Ladenburg Thalmann Healthcare Conference
CHAPEL HILL, N.C. --(BUSINESS WIRE)--Sep. 15, 2015-- POZEN Inc. (NASDAQ: POZN), a specialty pharmaceutical company, today announced that certain members of the executive management team will participate in the Ladenburg Thalmann Healthcare Conference to be held September 29, 2015 in New York .
Toggle Summary POZEN Appoints James P. Tursi, M.D. Chief Medical Officer
CHAPEL HILL, N.C. --(BUSINESS WIRE)--Sep. 14, 2015-- POZEN Inc. (NASDAQ:POZN) , today announced that James P. Tursi, M.D. will be appointed Chief Medical Officer of POZEN , effective October 1, 2015 . Dr. Tursi will report to Adrian Adams , Chief Executive Officer of POZEN , and will be responsible
Toggle Summary POZEN Reports Second Quarter 2015 Results
-Strategic Merger with Tribute Pharmaceuticals Expected to Close in the 4Q 2015- -Commercialization Plans for YOSPRALA TM Underway- CHAPEL HILL, N.C. --(BUSINESS WIRE)--Aug. 10, 2015-- POZEN Inc. (NASDAQ:POZN) , today announced results for the second quarter ended June 30, 2015 .
Toggle Summary POZEN Announces August 10th Webcast of Second Quarter 2015 Results
CHAPEL HILL, N.C. --(BUSINESS WIRE)--Jul. 27, 2015-- POZEN Inc. (NASDAQ: POZN) announced today that it plans to release second quarter 2015 results on August 10, 2015 , before the market opens. The announcement will be followed by a live webcast at 2:00 p.m.
Toggle Summary POZEN Appoints Scott Charles Senior Vice President of Finance
Charles to Serve as Chief Financial Officer of Aralez Following Completion of Merger with Tribute Pharmaceuticals CHAPEL HILL, N.C. --(BUSINESS WIRE)--Jul. 27, 2015-- POZEN Inc. (“POZEN”) (NASDAQ:POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced
Toggle Summary POZEN Announces Key Leadership Additions
Three New Executives, Each Bring Decades of Experience Working at High Growth Pharmaceutical Companies New Executives Will Also Serve on Leadership Team of Aralez Pharmaceuticals , Following Completion of Merger with Tribute CHAPEL HILL, N.C. --(BUSINESS WIRE)--Jun. 22, 2015-- POZEN Inc.
Toggle Summary POZEN Announces Strategic Acquisition of Tribute and Growth Capital Commitment from Leading Healthcare Sponsors
Transformative Transaction Creates Premier Specialty Pharma Company Focused on Cardiovascular Treatments US$350 Million Capital Commitment from Deerfield-Led Syndicate to Fund Commercial Launch and Pursue Strategic Acquisitions and Growth Opportunities Adrian Adams Will Lead World-Class Management
Toggle Summary POZEN Forms an Irish Subsidiary and Enters into an Intangible Property Transfer Arrangement
CHAPEL HILL, N.C. --(BUSINESS WIRE)--Jun. 2, 2015-- POZEN Inc. (NASDAQ: POZN) , a pharmaceutical company committed to developing medicine that transforms lives, today announced that it has formed POZEN Limited , a wholly owned Irish subsidiary and has entered in an Intangible Property Transfer
Toggle Summary POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO
CHAPEL HILL, N.C. --(BUSINESS WIRE)--Jun. 1, 2015-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced that John R. Plachetka, Pharm.D., its founder, Chairman, Chief Executive Officer and President is retiring, effective
Toggle Summary POZEN Reports First Quarter 2015 Results
CHAPEL HILL, N.C. --(BUSINESS WIRE)--May 8, 2015-- POZEN Inc. (NASDAQ: POZN) , a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2015 . Corporate Highlights Q1 2015 was the fourth consecutive quarter of
Toggle Summary POZEN Announces May 8th Webcast of First Quarter 2015 Results
CHAPEL HILL, N.C. --(BUSINESS WIRE)--May 4, 2015-- POZEN Inc. (NASDAQ: POZN) , a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release first quarter 2015 results on May 8, 2015 , before the market opens.
Toggle Summary POZEN Reports Fourth Quarter and Year End 2014 Results
- Reports Annual Net Income of $19.7 Million , Including VIMOVO Royalty of $21.1 Million - - Updates Anticipated Commercialization Timing - CHAPEL HILL, N.C. --(BUSINESS WIRE)--Mar. 9, 2015-- POZEN Inc. (NASDAQ: POZN) , a pharmaceutical company committed to transforming medicine that transforms
Toggle Summary POZEN Announces March 9th Webcast of Fourth Quarter and Year End 2014 Results
CHAPEL HILL, N.C. --(BUSINESS WIRE)--Mar. 4, 2015-- POZEN Inc. (NASDAQ: POZN) , a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release fourth quarter and year end 2014 results on March 9, 2015 , before the market opens.
Toggle Summary POZEN Announces Issuance of VIMOVO® Related Patent by the United States Patent and Trademark Office
CHAPEL HILL, N.C. --(BUSINESS WIRE)--Feb. 4, 2015-- POZEN Inc. (NASDAQ: POZN) , a pharmaceutical company committed to transforming medicine that transforms lives, today announced the issuance of a patent by the United States Patent and Trademark Office (USPTO) entitled “Method for Treating a

Copyright Nasdaq. Minimum 15 minutes delayed.